Beware the Siren Song of BioScience

A number of venture capital firms, still wary about diving back into technology investing, have instead turned their sights and their funding toward biotechnology and bioscience – a decision some VCs believe will ultimately prove a mistake.

“You’re seeing a lot of venture funds make investments in bioscience because they can’t find a way to justify investments in technology to their limited partners, and that doesn’t make sense,” says Jonathan Silver, managing director and founder of Core Capital.

PE Week subscribers can read the rest of this story in the protected Weekly Headlines section, or in the latest print edition. Click here to subscribe.